CSN Login
Members Online: 4

You are here

Piqray Patient Recruitment--Breast Cancer Patients

Date: 
Monday, March 29, 2021 - 1:45pm
Your announcement.: 

My name is MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

The Canadian government will soon be reviewing the use of Piqray (alpelisib) to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer after disease progression following treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor. Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

Does this survey apply to you?

We are looking for patients with HR-positive, HER2-negative, PIK3CA-mutated, metastatic breast cancer and patients who have been treated with Piqray to talk about their treatment experience.

YOU DO NOT NEED TO LIVE IN CANADA TO PARTICIPATE.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/piqray

If you would like to speak with us directly about your cancer or treatment experience, you can contact me at survey@rethinkbreastcancer.com.

MJ DeCoteau
Founder + Executive Director
Rethink Breast Cancer

 

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
Contact - Email: 
survey@rethinkbreastcancer.com
Contact - First name: 
MJ
Contact - Last name: 
DeCouteau
Subscribe to Comments for "Piqray Patient Recruitment--Breast Cancer Patients"